Latest & greatest articles for ciprofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ciprofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ciprofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ciprofloxacin

1. Ciprofloxacin resistance in hospital and community-acquired urinary tract infections by escherichia coli: a systematic review and meta-analysis

Ciprofloxacin resistance in hospital and community-acquired urinary tract infections by escherichia coli: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

2. Meningococcal disease and ciprofloxacin: PGD template

Meningococcal disease and ciprofloxacin: PGD template Meningococcal disease and ciprofloxacin: PGD template - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search The United Kingdom is leaving the European Union on 31 October 2019. Guidance Meningococcal disease and ciprofloxacin: PGD template Patient group direction (PGD) template to supply or administer ciprofloxacin for meningococcal disease clusters in educational (...) version of PGD template. 6 June 2018 Updated 'Meningococcal disease: PGD template for the supply or administration of ciprofloxacin'. 17 February 2017 First published. Related content Collection Explore the topic Is this page useful? Thank you for your feedback Help us improve GOV.UK Don’t include personal or financial information like your National Insurance number or credit card details. What were you doing? What went wrong? Send Help us improve GOV.UK To help us improve GOV.UK, we’d like to know

2019 Public Health England

3. Ciprofloxacin (Cetraxal) - treatment of acute otitis externa

Ciprofloxacin (Cetraxal) - treatment of acute otitis externa Final Appraisal Recommendation Advice No: 1218 – July 2018 Ciprofloxacin (Cetraxal ® ) 2 mg/ml ear drops solution in a single dose container Limited submission by Aspire Pharma Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1343), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (...) (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Ciprofloxacin (Cetraxal ® ) is recommended as an option for use within NHS Wales for the treatment of acute otitis externa in adults and children older than 1 year with an intact

2018 All Wales Medicines Strategy Group

4. Ciprofloxacin

Ciprofloxacin Top results for ciprofloxacin - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ciprofloxacin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

5. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial Full Text available with Trip Pro

Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial Antibiotic prophylaxis for contacts of meningitis cases is not recommended during outbreaks in the African meningitis belt. We assessed the effectiveness of single-dose oral ciprofloxacin administered to household contacts and in village-wide distributions on the overall attack rate (AR) in an outbreak of meningococcal (...) meningitis.In this 3-arm, open-label, cluster-randomized trial during a meningococcal meningitis outbreak in Madarounfa District, Niger, villages notifying a suspected case were randomly assigned (1:1:1) to standard care (the control arm), single-dose oral ciprofloxacin for household contacts within 24 hours of case notification, or village-wide distribution of ciprofloxacin within 72 hours of first case notification. The primary outcome was the overall AR of suspected meningitis after inclusion. A random

2018 EvidenceUpdates Controlled trial quality: predicted high

6. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial (Abstract)

Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen. This study aims to investigate whether ciprofloxacin once weekly administration is not inferior to norfloxacin once daily administration for the prevention of SBP.This is an investigator-initiated open-label (...) randomized controlled trial conducted at seven tertiary hospitals in South Korea. Liver cirrhosis patients with ascites were screened, and enrolled in this randomized controlled trial if ascitic protein ≤1.5 g/dL or the presence of history of SBP. Ascitic polymorphonucleated cell count needed to be <250/mm3. Patients were randomly assigned into norfloxacin daily or ciprofloxacin weekly group, and followed-up for 12 months. Primary endpoint was the prevention of SBP.One hundred twenty-four patients met

2018 EvidenceUpdates

7. Ciprofloxacin ear drops (Cetraxal) - acute otitis externa

Ciprofloxacin ear drops (Cetraxal) - acute otitis externa Published 9 April 2018 Product Update: ciprofloxacin ear drops solution, single dose container 2mg/mL (Cetraxal ® ) SMC No 1320/18 Aspire Pharma Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) ciprofloxacin ear drops (Cetraxal ® ) are accepted for restricted use within NHS Scotland. Indication under review: treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. SMC restriction: when off-label or unlicensed ciprofloxacin formulations would otherwise be used. Ciprofloxacin eye drops (used off-label) or unlicensed ciprofloxacin ear drops have been in use in NHS Scotland for this indication

2018 Scottish Medicines Consortium

8. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Full Text available with Trip Pro

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria.Patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in 14- or 28-day on/off treatment cycles for 48 weeks (...) . Primary end-points were time to first exacerbation and frequency of exacerbations. Enrolling countries and α level split (0.049 and 0.001 for 14- and 28-day cycles, respectively) differed from RESPIRE 1.Patients were randomised to ciprofloxacin DPI (14 days on/off (n=176) or 28 days on/off (n=171)) or placebo (14 days on/off (n=88) or 28 days on/off (n=86)). The exacerbation rate was low across treatment arms (mean±sd 0.6±0.9). Active treatment showed trends to prolonged time to first exacerbation

2018 EvidenceUpdates

9. Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin Full Text available with Trip Pro

Transcriptome Profiling Reveals Interplay of Multifaceted Stress Response in Escherichia coli on Exposure to Glutathione and Ciprofloxacin We have previously reported that supplementation of exogenous glutathione (GSH) promotes ciprofloxacin resistance in Escherichia coli by neutralizing antibiotic-induced oxidative stress and by enhancing the efflux of antibiotic. In the present study, we used a whole-genome microarray as a tool to analyze the system-level transcriptomic changes of E. coli (...) on exposure to GSH and/or ciprofloxacin. The microarray data revealed that GSH supplementation affects redox function, transport, acid shock, and virulence genes of E. coli. The data further highlighted the interplay of multiple underlying stress response pathways (including those associated with the genes mentioned above and DNA damage repair genes) at the core of GSH, offsetting the effect of ciprofloxacin in E. coli. The results of a large-scale validation of the transcriptomic data using reverse

2018 mSystems

10. Safety of ciprofloxacin in paediatrics: a systematic review

Safety of ciprofloxacin in paediatrics: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

11. Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis (SBP): a network meta-analysis

Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis (SBP): a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

13. Ciloxan (Ciprofloxacin) - otitis externa or otitis media

Ciloxan (Ciprofloxacin) - otitis externa or otitis media 1/16 The legally binding text is the original French Version TRANSPARENCY COMMITTEE OPINION 19 October 2011 CILOXAN 3 mg/ml, ear drops, solution B/1 bottle of 5 ml (CIP code: 3601303) Applicant: ALCON FRANCE Ciprofloxacin ATC code: S02AA (antibiotic from the fluoroquinolone family) List I Date of Marketing Authorisation: 28 November 2002, amendment of 14 May 2008 Reason for request: Inclusion on the list of medicines refundable (...) by National Health Insurance and approved for hospital use. Medical, Economic and Public Health Assessment Division 2/16 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient Ciprofloxacin 1.2. Indication "Antibiotic treatment for adults and children from 1 year: - for acute otitis externa - for purulent otorrhea of the mastoid cavity and chronic suppurative otitis media with tympanic perforation. Consideration should be given to official guidance on the appropriate use of antibacterial agents

2014 Haute Autorite de sante

14. Comparing the prevalence of ciprofloxacin resistance in community-acquired versus hospital-acquired E. coli urinary tract infections: systematic review and meta-analysis

Comparing the prevalence of ciprofloxacin resistance in community-acquired versus hospital-acquired E. coli urinary tract infections: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2014 PROSPERO

15. Ciprofloxacin

Ciprofloxacin USE OF CIPROFLOXACIN IN PREGNANCY 0344 892 0909 USE OF CIPROFLOXACIN IN PREGNANCY (Date of issue: June 2017 , Version: 3.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary The quinolones (including ciprofloxacin, levofloxacin (...) , moxifloxacin, nalidixic acid, norfloxacin and ofloxacin) are broad-spectrum synthetic antibiotics used in the treatment of a wide variety of infections including those of the urinary tract, respiratory-tract, gastro-intestinal system, bones and joints, as well as gonorrhoea, chlamydia and septicaemia. Ciprofloxacin is also used in the treatment or post-exposure prophylaxis of anthrax. No increased risk of congenital malformations overall, low birth weight, preterm delivery, intrauterine death or neonatal

2014 UK Teratology Information Service

16. Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectiou (Abstract)

Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectiou This double-blind, multicenter trial compared the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy in low-risk febrile neutropenic patients with cancer.Inclusion criteria were cancer, febrile (...) neutropenia, low risk of complications as predicted by a Multinational Association for Supportive Care in Cancer (MASCC) score > 20, ability to swallow, and ≤ one single intravenous dose of empiric antibiotic therapy before study drug treatment initiation. Early discharge was encouraged when a set of predefined criteria was met. Patients received either moxifloxacin (400 mg once daily) monotherapy or oral ciprofloxacin (750 mg twice daily) plus amoxicillin/clavulanic acid (1,000 mg twice daily). The trial

2013 EvidenceUpdates Controlled trial quality: predicted high

17. Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness

Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness DATE: 27 November 2012 CONTEXT AND POLICY ISSUES The potential use of anthrax as a biological terrorist attack has

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. (Abstract)

Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Acute pyelonephritis is a common infection in adult women, but there is a paucity of controlled trials of its treatment and the optimum duration of antibiotic treatment has not been properly defined. We compared the efficacy of ciprofloxacin for 7 days and 14 days in women with community-acquired acute pyelonephritis.In a prospective (...) , non-inferiority trial undertaken at 21 centres of infectious diseases in Sweden, women (aged ≥18 years) who were not pregnant and had a presumptive diagnosis of acute pyelonephritis were randomly assigned to oral treatment with ciprofloxacin 500 mg twice daily for 7 days or 14 days. The first week was open label. A computer-generated randomisation list in block sizes of two was used for treatment allocation in a 1:1 ratio. The study was double-blind and placebo-controlled during the second week

2012 Lancet Controlled trial quality: predicted high

19. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. Full Text available with Trip Pro

Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. Although fluoroquinolones remain the most reliable urinary antimicrobial, resistance rates have increased and effective fluoroquinolone-sparing antimicrobials are needed.To determine whether cefpodoxime is noninferior to ciprofloxacin for treatment of acute cystitis.Randomized, double-blind trial of 300 women aged 18 to 55 years with acute uncomplicated cystitis comparing ciprofloxacin (...) (n = 150) with cefpodoxime (n = 150); patients were from a student health center in Seattle, Washington, and a referral center in Miami, Florida. The study was conducted from 2005 to 2009 and outcomes were assessed at 5 to 9 days and 28 to 30 days after completion of therapy. Intent-to-treat and per-protocol analyses were performed; 15 women in the ciprofloxacin group and 17 women in the cefpodoxime group were lost to follow-up.Patients were given 250 mg of ciprofloxacin orally twice daily for 3

2012 JAMA Controlled trial quality: predicted high

20. Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review

Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Clinical equivalency of ciprofloxacin 750mg enterally and 400mg intravenously for patients receiving enteral feeding: systematic review Chui D, Cheng L, Tejani AM CRD summary This review reported that there was insufficient (...) evidence to determine whether twice daily doses of 750mg enteral or 400mg intravenous ciprofloxacin were more effective in adult patients who received enteral feeds. Despite a risk of publication bias and lack of a validity assessment, the findings of the review appear reliable given the very limited evidence. Authors' objectives To compare the effects of 750mg enteral and 400mg intravenous ciprofloxacin for adult patients receiving enteral feeding. Searching EMBASE and MEDLINE were searched for fully

2009 DARE.